並列摘要
Currently immunosuppressive agents for kidney transplantation can be classified into three categories: induction agents, maintenance therapy, and treatment for rejection. This article is focused on induction therapy. Induction agents can be defined as T-cell depleting, B- and T-cell depleting, and nondepleting T-cell agents. We will focus on the pharmacology, efficacy, major side effects including infection and malignancy, and how to choose an appropriate induction regimen for individualized kidney recipients according to risk and benefit assessment.
延伸閱讀
- 闕士傑、王碩盟、賴明坤（2007）。腎臟移植。台灣醫學，11(1)，62-69。https://doi.org/10.6320/FJM.2007.11(1).11
- 李俊仁、陳宏癸（1989）。腎臟移植。健康世界，(160)，42-47。https://doi.org/10.6454/HW.198904.0042
- 蔡孟昆（2003）。腎臟移植：談移植腎的使用壽命。健康世界，(209)，23-26。https://doi.org/10.6454/HW.200305.0006
- 王家良、楊得政、王守玠、張淑鈺、黃春森（2012）。移植腎急性排斥治療的新進展。腎臟與透析，24(2)，107-111。https://doi.org/10.6340/KD.2012(2).07
- 鍾麗娟（2003）。The Patient Education for Waiting Patients for Kidney Transplantation。臺灣腎臟護理學會雜誌，2(1)，20-27。https://www.airitilibrary.com/Article/Detail?DocID=17267404-200303-2-1-20-27-a